|
TRMT12 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
1.21159999999509E-06 |
| Normal-vs-Stage3 |
1.99840144432528E-15 |
| Normal-vs-Stage4 |
1.62525548574877E-12 |
| Stage1-vs-Stage2 |
4.968200E-02 |
| Stage1-vs-Stage3 |
2.955400E-01 |
| Stage1-vs-Stage4 |
2.073600E-02 |
| Stage2-vs-Stage3 |
1.704470E-02 |
| Stage2-vs-Stage4 |
9.988900E-04 |
| Stage3-vs-Stage4 |
1.702580E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.014400E-04 |
| Normal-vs-Asian |
5.51040324481278E-11 |
| Caucasian-vs-AfricanAmerican |
2.158100E-02 |
| Caucasian-vs-Asian |
5.261400E-01 |
| AfricanAmerican-vs-Asian |
8.218100E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62414526272414E-12 |
| Male-vs-Female |
1.545210E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
2.22044604925031E-16 |
| Normal-vs-Age(61-80Yrs) |
5.91027227159202E-12 |
| Normal-vs-Age(81-100Yrs) |
1.680980E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.666000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.933600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.466000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.257400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.987000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.674800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.500620E-03 |
| Classical-VS-Follicular |
3.095900E-02 |
| Classical-VS-Other |
2.856000E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
4.30390000000225E-05 |
| Tall-VS-Other |
7.326000E-01 |
| Tall-VS-Normal |
1.4432899320127E-15 |
| Follicular-VS-Other |
1.315960E-01 |
| Follicular-VS-Normal |
1.16719999998516E-07 |
| Other-VS-Normal |
3.93309999999758E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.12052597703405E-14 |
| Normal-vs-N1 |
1.11022302462516E-16 |
| N0-vs-N1 |
2.044900E-04 |
|
|
